17α-hydroxyprogesterone caproate versus intravaginal progesterone in IVF-embryo transfer cycles: A prospective randomized study

Reproductive BioMedicine Online

Volumn 9, Issue 1, 2004, Pages 17-21

  Unfer, Vittorio ^a   Casini, Maria Luisa ^b   Costabile, Loredana ^a   Gerli, Sandro ^c   Baldini, Domenico ^d   Di Renzo, G C ^c  

^a Obstetrics and Gynecology Centre   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

^d Private Hosp Casa Cura Santa Maria   (Italy)

Author keywords

17 hydroxyprogesterone caproate; IVF embryo transfer; Luteal phase support; Progesterone administration

Indexed keywords

CHORIONIC GONADOTROPIN; GONADORELIN DERIVATIVE; HYDROXYPROGESTERONE CAPROATE; PROGESTERONE; RECOMBINANT FOLLITROPIN;

ADULT; ARTICLE; BIOCHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; EMBRYO TRANSFER; FEMALE; FERTILIZATION IN VITRO; HUMAN; LUTEAL PHASE; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; NIDATION; OUTCOMES RESEARCH; PREGNANCY COMPLICATION; PREGNANCY RATE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REPRODUCTIVE SUCCESS; SPONTANEOUS ABORTION;

EID: 3242726825     PISSN: 14726483     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-6483(10)62104-9     Document Type: Article

References (27)

1. Abate A, Perino M, Abate FG et al. 1999 Intramuscular versus vaginal administration of progesterone for luteal phase support after in vitro fertilization and embryo transfer. A comparative randomized study. Clinical and Experimental Obstetrics and Gynecology 26, 203-206.
2. Aksel S, Jones GS 1974 Effect of progesterone and 17-hydroxyprogesterone caproate on normal corpus luteum function. American Journal of Obstetrics and Gynecology 15, 466-472.
3. Artini PG, Volpe A, Angioni S et al. 1995 A comparative, randomized study of three different progesterone support of the luteal phase following IVF/ET program. Journal of Endocrinological Investigation 18, 51-56.
4. Capitanio GL, Ubaldi F, Giannini P, Croce S 1992 Luteal phase defects in assisted reproduction: the role of luteal phase supplementation. Acta Europaea Fertilitatis 23, 15-19.
5. Chantilis SJ, Zeitoun KM, Patel SI et al. 1999. Use of Crinone vaginal progesterone gel for luteal support in in vitro fertilization cycles. Fertility and Sterility 72, 823-829.
6. Costabile L, Gerli S, Manna C et al. 2001. A prospective randomised study comparing intramuscular progesterone and 17-alpha-hydroxyprogesterone caproate in patients undergoing in vitro fertilization-embryo transfer cycles. Fertility and Sterility 76, 394-396.
7. Damario MA, Goudas VT, Session DR et al. 1999 Crinone 8% vaginal progesterone gel results in lower embryonic implantation efficiency after in vitro fertilization-embryo transfer. Fertility and Sterility 72, 830-836.
8. Davis ME, Wied G 1955 17-Alpha-hydroxyprogesterone caproate: a new substance with prolonged progestational activity. A comparison with chemically pure progesterone. Journal of Clinical Endocrinology and Metabolism 15, 923-930.
9. Goldzieher JW 1957 Lack of androgenicity of 17-hydroxyprogesterone or its 17-caproate ester. Journal of Clinical Endocrinology and Metabolism 17, 323-325.
10. Hendrickx A, Korte R, Leushener B et al. 1987. Embryotoxicity of sex steroidal hormones in nonhuman primates: II. Hydroxyprogesterone caproate, estradiol valerate. Teratology, 35, 129-136.
11. Johnson J, Austin K, Jones G et al. 1975. Efficacy of 17alphahydroxyprogesterone caproate in the prevention of premature labor. New England Journal of Medicine 293, 675-680.
12. Licciardi FL, Kwiatkowski A, Noyes NL et al. 1999. Oral versus intramuscular progesterone for in vitro fertilization: a prospective randomized study. Fertility and Sterility 71, 614-618.
13. Meis PJ, Klebanoff M, Thom E et al. 2003. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. New England Journal of Medicine 12, 2379-2385.
14. Penzias AS 2002 Luteal phase support. Fertility and Sterility 77, 318-323.
15. Penzias AS, Alper MM 2003 Luteal support with vaginal micronized progesterone gel in assisted reproduction. Reproductive BioMedicine Online 6, 287-295.
16. Pritts EA, Atwood AK 2002 Luteal phase support in infertility treatment: a meta-analysis of the randomized trials. Human Reproduction 17, 2287-2299.
17. Propst AM, Hill JA, Ginsburg ES et al. 2001 A randomized study comparing Crinone 8% and intramuscular progesterone supplementation in in vitro fertilization-embryo transfer cycles. Fertility and Sterility 76, 1144-1149.
18. Sas M, Farkas M, Szegvari M 1967 Effectiveness of 17-hydroxyprogesterone caproate (Hormofort) in clinical practice. Therapia Hungurica 15, 21-26.
19. Sauer MV, Stein AL, Paulson RJ, Moyer DL 1991 Endometrial responses to various hormone replacement regimens in ovarian failure patients preparing for embryo donation. International Journal of Gynaecology and Obstetrics 35, 61-68.
20. Schally AV 1999 LH-RH analogues: I. Their impact on reproductive medicine. Gynecological Endocrinology 13, 401-409.
21. Schulze PE 1958 Preparation of 17 alpha-hydroxy-progesterone caproate-(4-C14). Zeitung Naturforsch B 13B, 409-410.
22. Shearman RP, Garrett WJ 1963 Double-blind study of effect of 17-hydroxyprogesterone caproate on abortion rate. British Medical Journal 5326, 292-295.
23. Smitz J, Devroey P, Faguer B et al. 1992 A prospective randomized comparison of intramuscular or intravaginal natural progesterone as a luteal phase and early pregnancy supplement. Human Reproduction 7, 168-175.
24. Soliman S, Daya S, Collins J et al. 1994 The role of luteal phase support in infertility treatment: a meta-analysis of randomized trials. Fertility and Sterility 61, 1068-1076.
25. Tavaniotou A, Albano C, Smitz J, Devroey P 2002 Impact of ovarian stimulation on corpus luteum function and embryonic implantation. Journal of Reproductive Immunology 55, 123-130.
26. Valbuena D, Jasper M, Remohi J et al. 1999 Ovarian stimulation and endometrial receptivity. Human Reproduction 14, 107-111.
27. Wang HS, Soong YK 1996 Transvaginal progesterone supplementation increases serum insulin-like growth factor-binding protein-1 levels. Gynecological Endocrinology 10, 349-355.